This company has been marked as potentially delisted and may not be actively trading. Dicerna Pharmaceuticals (DRNA) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock DRNA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Arrowhead Pharmaceuticals (NASDAQ: ARWR)May 25, 2023 | fool.com'Mad Money' Lightning Round: I'm Staying Away From Five BelowFebruary 16, 2023 | thestreet.comBiondVax Pharmaceuticals Stock (NASDAQ:BVXV), Quotes and News SummaryFebruary 7, 2023 | benzinga.comMyc Proto-Oncogene Protein Market 2023 Statistics, Industry Share, Latest Trends, Growth Drivers, Size Estimate and Forecast till 2028January 26, 2023 | marketwatch.comWe Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business GrowthJanuary 18, 2023 | finance.yahoo.comDRNA Jan 2022 22.500 callJanuary 14, 2022 | ca.finance.yahoo.comDRNA Jul 2022 40.000 call(CONTRJanuary 14, 2022 | ca.finance.yahoo.comNovo Nordisk Announces Completion of Dicerna Pharmaceuticals AcquisitionDecember 28, 2021 | finance.yahoo.comDicerna Pharmaceuticals (Nasdaq:DRNA) HeadlineTrading was temporarily halted for "DRNA" at 07:12 PM with a stated reason of "News pending."...December 28, 2021 | marketbeat.comDicerna Pharmaceuticals (NASDAQ:DRNA) Receives Buy Rating from SVB LeerinkNovember 25, 2021 | marketbeat.comDICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNANovember 19, 2021 | prnewswire.comSHAREHOLDER ALERT: WeissLaw LLP Investigates Dicerna Pharmaceuticals, Inc.November 19, 2021 | finance.yahoo.comDICERNA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of DRNA and Encourages Investors to Contact the FirmNovember 18, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Dicerna Pharmaceuticals, Inc. to Novo NordiskNovember 18, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Dicerna Pharmaceuticals, Inc.November 18, 2021 | finance.yahoo.comDicerna Stock Skyrockets as Novo Nordisk to Buy Research Partner for $3.3 BillionNovember 18, 2021 | barrons.comUPDATE 3-Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billionNovember 18, 2021 | finance.yahoo.comDicerna Pharmaceuticals (Nasdaq:DRNA) HeadlineTrading was temporarily halted for "DRNA" at 06:11 AM with a stated reason of "News pending."...November 18, 2021 | marketbeat.comDicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021November 12, 2021 | finance.yahoo.comDicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With LillyNovember 12, 2021 | finance.yahoo.comDicerna Pharmaceuticals's Return On Capital Employed OverviewNovember 10, 2021 | benzinga.comDicerna Pharmaceuticals: Q3 Earnings SnapshotNovember 9, 2021 | sfgate.comDicerna Announces Third Quarter 2021 Financial Results and Provides a Business UpdateNovember 9, 2021 | finance.yahoo.comDicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021November 4, 2021 | finance.yahoo.comHedge Fund Sentiment Is Stagnant On Dicerna Pharmaceuticals Inc (DRNA)October 18, 2021 | finance.yahoo.comDicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021October 15, 2021 | finance.yahoo.comDicerna Highlights Will Give Poster Presentations At American Association For Study Of Liver Nov. 12-15, 2021October 14, 2021 | benzinga.comDicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in NovemberOctober 14, 2021 | finance.yahoo.comDicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use DisorderSeptember 28, 2021 | finance.yahoo.comDicerna Announces New Executive Leadership AppointmentsSeptember 22, 2021 | finance.yahoo.comWhere Dicerna Pharmaceuticals Stands With AnalystsAugust 21, 2021 | markets.businessinsider.comZacks Investment Research Upgrades Dicerna Pharmaceuticals (NASDAQ:DRNA) to "Hold"August 19, 2021 | marketbeat.comDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Analysts Are More Bearish Than They Used To BeAugust 15, 2021 | nasdaq.comDicerna Pharmaceuticals Inc (DRNA) President and CEO Douglas Fambrough Bought $110,500 of SharesAugust 13, 2021 | finance.yahoo.comIs Dicerna Stock a Buy Right Now? This Is What You Need to KnowAugust 10, 2021 | finance.yahoo.comDicerna Pharmaceuticals, inc (DRNA) Q2 2021 Earnings Call TranscriptAugust 9, 2021 | finance.yahoo.comDicerna Pharmaceuticals: Q2 Earnings InsightsAugust 9, 2021 | benzinga.comDicerna Pharmaceuticals: Q2 Earnings SnapshotAugust 9, 2021 | sfgate.comDicerna Announces Second Quarter 2021 Financial Results and Provides a Business UpdateAugust 9, 2021 | finance.yahoo.comCitigroup Lowers Dicerna Pharmaceuticals (NASDAQ:DRNA) to NeutralAugust 9, 2021 | marketbeat.comAnalyst Ratings For Dicerna PharmaceuticalsAugust 6, 2021 | markets.businessinsider.comDicerna Pharmaceuticals Drops on Mixed Drug-Trial ResultsAugust 6, 2021 | finance.yahoo.comDicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary HyperoxaluriaAugust 5, 2021 | finance.yahoo.comDicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021August 2, 2021 | finance.yahoo.comDicerna Pharmaceuticals (DRNA) to Report Q2 Results: Wall Street Expects Earnings GrowthJuly 29, 2021 | finance.yahoo.comDicerna posts interim results from early-stage belcesiran liver disease trialJuly 23, 2021 | seekingalpha.com Get Dicerna Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DRNA Media Mentions By Week DRNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DRNA News Sentiment▼0.001.11▲Average Medical News Sentiment DRNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DRNA Articles This Week▼00▲DRNA Articles Average Week Get the Latest News and Ratings for DRNA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Dicerna Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Jyong Biotech News MorphoSys News Calliditas Therapeutics AB (publ) News Zymeworks News MBX Biosciences News Aerovate Therapeutics News Cybin News Virios Therapeutics News OS Therapies News Eliem Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DRNA) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dicerna Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dicerna Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRNA Stock Alerts